Oral peptide drugs Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines oral peptide drugs, peptide medicines taken by mouth instead of by injection, made possible by absorption enhancers, macrocyclic designs and other delivery technologies. It tests how fast oral delivery moves from the first approvals into obesity, psoriasis and cardiovascular disease, and which participants capture value among developers, large pharmaceutical firms, peptide manufacturers and delivery technology suppliers.

Oral delivery has now reached the largest drug markets. The FDA approved the Wegovy pill, oral semaglutide 25 mg, for weight management on 22 December 2025, and it launched in the United States in January 2026. In the OASIS 4 trial weight loss was 16.6% on treatment against 2.7% on placebo at 64 weeks, and 13.6% against 2.2% regardless of adherence. The conclusion is that an oral peptide can deliver weight loss close to the injectable version, even though oral bioavailability is about 1% and the tablet must be taken after a 30 minute fast with a small amount of water.

Approvals have spread beyond obesity. The FDA approved icotrokinra (Icotyde), an oral peptide that blocks the IL-23 receptor, on 17 March 2026, after a Phase 3 trial in which 65% of patients had clear or almost clear skin at week 16 against 8% on placebo. The FDA approved enlicitide (Lipfendra), an oral PCSK9 inhibitor from Merck, on 15 July 2026, after a Phase 3 trial that lowered LDL cholesterol by 57.1% at week 24 against a 3.0% rise on placebo. The conclusion is that oral peptides now work on immune and cardiovascular targets that were reached only by injection or antibody.

Competition and capital are moving fast. The oral non-peptide GLP-1 orforglipron (Foundayo) was approved by the FDA on 1 April 2026, with oral bioavailability of about 79% and no fasting rule, Samsung Biologics offered about USD 1.8 billion for the peptide manufacturer PolyPeptide in July 2026, and Gilead agreed in October 2026 to buy an oral IL-23 receptor peptide programme from PepStar for USD 1.275 billion. The conclusion is that peptide manufacturing capacity and oral delivery know-how are being bought at scale, and that small molecule oral drugs compete directly for the obesity market.

The brief treats oral peptide drugs as an accelerating category with an eight year horizon to 2034. It identifies which diseases, regions and operators scale first and what each means for developers, large pharmaceutical firms and manufacturers.

It is a focused 106-page decision brief for biopharma firms, manufacturers and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which diseases scale first and who captures value.

Absorption enhancer tablets protect the peptide in the stomach and help it cross the stomach lining. Oral semaglutide uses this approach and is the first oral GLP-1 approved for diabetes and for weight management.

Macrocyclic and engineered peptides are designed to resist digestion and reach their target. Enlicitide is a macrocyclic oral PCSK9 inhibitor, and icotrokinra is an oral peptide that blocks the IL-23 receptor.

Capsules, devices and other delivery systems are in earlier development, and one oral octreotide was approved for acromegaly in 2020.

Uses are obesity, type 2 diabetes, psoriasis, hypercholesterolaemia and acromegaly, each under small molecule and peptide drug regulation.

The limits are low bioavailability and high doses, administration restrictions, gastrointestinal effects and competition from non-peptide oral drugs. The period turns on whether outcomes data and manufacturing capacity support use at the scale of obesity.

The oral peptide drugs market, covering sales of marketed oral peptide drugs such as oral semaglutide, oral octreotide, icotrokinra and enlicitide, related licensing and collaboration revenue, and related peptide manufacturing and delivery technology services, is valued at USD 6–8 billion in 2026 and is projected to reach USD 29.45–39.26 billion by 2034, at a CAGR of 22%.

The 2026 base rests on sales of marketed oral peptides, licensing and collaboration income, and peptide manufacturing and delivery technology services. Growth then follows prescription growth of the oral obesity peptide, approvals of new oral peptides and wider indications.

The forecast is sensitive to prescription volumes, pricing, competition from non-peptide oral drugs, outcomes data and peptide manufacturing capacity. Regionally, North America leads on prescriptions and launches, Europe on approvals and manufacturing, and Asia-Pacific on CDMO capacity and fast following developers.

The base case assumes the oral obesity peptide keeps gaining prescriptions, outcomes data for oral cholesterol and obesity drugs report around 2028 and 2029, and new oral peptides are approved, giving the inflection in 2030. An accelerated case assumes faster uptake and earlier approvals of oral peptides for immune disease, bringing the inflection to 2029 and lifting the 2034 value to the top of the range. A delayed case assumes price pressure and share loss to non-peptide oral drugs, holding growth at the bottom of the range.

Growth drivers

• Patients unwilling or unable to use injections.
• Approved oral peptides in obesity, diabetes, psoriasis and cholesterol.
• Prescription growth of the first oral obesity peptide.
• Extension to immune and cardiovascular disease.

Enablers

• Venture funding and financing rounds.
• Biopharma licensing and partnerships.
• Public research funding.
• Peptide manufacturing capacity.

Restraints and barriers

• Low bioavailability and high dose.
• Competition from non-peptide oral drugs and injectables.
• Administration restrictions and adherence.
• Cost and complexity of manufacture.

The direction of oral peptide drugs is set by the need for oral alternatives to injections, regulation, new oral targets and delivery systems, biopharma dealmaking and partnering, and manufacturing cost.

The key participants in oral peptide drugs include Novo Nordisk A/S, Eli Lilly and Company, Johnson & Johnson, Protagonist Therapeutics, Inc., Merck & Co., Inc., Gilead Sciences, Inc., Samsung Biologics Co., Ltd., PolyPeptide Group AG, Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bachem Holding AG, Lonza Group Ltd, Rani Therapeutics Holdings, Inc., Enteris BioPharma, Inc., Sanofi, Zealand Pharma A/S, Novartis AG, Bayer AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, PepStar, WeightWatchers International, Inc., American Diabetes Association, European Association for the Study of Diabetes, American Academy of Dermatology, American College of Cardiology, Mayo Clinic, Massachusetts General Hospital, U.S. Food and Drug Administration, European Medicines Agency, European Commission, Medicines and Healthcare products Regulatory Agency, National Institute for Health and Care Excellence, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, International Council for Harmonisation, Parenteral Drug Association and United States Pharmacopeia.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as oral peptide drugs mature.

Novo Nordisk leads on prescription scale with the oral obesity peptide, Johnson & Johnson with Protagonist Therapeutics and Merck lead the first approvals in psoriasis and cholesterol, Eli Lilly competes with a non-peptide oral drug, and Gilead and Samsung Biologics are buying capability, while manufacturers, clinical centres, regulators and standards bodies shape how fast oral peptides reach patients. Competitive intensity is high in obesity and moderate elsewhere in 2026, and it rises as new oral peptides are approved.

Where value migrates.

In 2026 value sits with the holder of the oral semaglutide franchise and with the first approvals in psoriasis and cholesterol, and with the CDMOs that make peptides. By 2030 it moves toward companies with several approved oral peptides, because payers and prescribers choose products with proven benefit and supply reliability. By 2034 it settles in integrated peptide design and manufacturing platforms and in CDMOs with peptide capacity at scale. Margins hold for products with outcomes data and narrow for late followers on shared targets.

The signals converge on rapid approvals and large transactions. The FDA approved oral peptides for obesity, psoriasis and cholesterol between December 2025 and July 2026, a manufacturer was the target of a USD 1.8 billion offer, and a Phase 1 oral peptide was priced at USD 1.275 billion. Each signal supports growth, and a non-peptide oral drug competes for the largest market.

Structural limits show where progress could slow: low bioavailability and high dose, administration restrictions, competition from non-peptide oral drugs and the cost of manufacture. The brief therefore tracks four indicators: prescription volumes, outcomes data, new approvals and peptide manufacturing capacity.

Obesity and diabetes, then psoriasis and cholesterol, then other immune and cardiovascular targets are the expected order of development.